Cargando…

Implications of dopaminergic medication withdrawal in Parkinson’s disease

The trajectory of the use of dopamine replacement therapy (DRT) in Parkinson’s disease (PD) is variable and doses may need to be increased, but also tapered. The plan for dose adjustment is usually done as per drug information recommendations from the licensing bodies, but there are no clear guideli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koschel, J., Ray Chaudhuri, K., Tönges, L., Thiel, M., Raeder, V., Jost, W. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2021
Materias:	Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319886/ https://www.ncbi.nlm.nih.gov/pubmed/34324057 http://dx.doi.org/10.1007/s00702-021-02389-x

Ejemplares similares

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Life style and Parkinson’s disease
por: Reichmann, Heinz, et al.
Publicado: (2022)

Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?
por: Chaudhuri, K. Ray, et al.
Publicado: (2013)

Parkinson’s: a syndrome rather than a disease?
por: Titova, Nataliya, et al.
Publicado: (2016)

Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
por: Tall, P., et al.
Publicado: (2023)

Theory of mind deficits in Parkinson’s disease are not modulated by dopaminergic medication
por: Usnich, Tatiana, et al.
Publicado: (2023)

Classification of advanced stages of Parkinson’s disease: translation into stratified treatments
por: Krüger, Rejko, et al.
Publicado: (2017)

Data-driven subtyping of Parkinson’s disease: comparison of current methodologies and application to the Bochum PNS cohort
por: Chen, Qiang, et al.
Publicado: (2023)

Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes
por: Schröter, Nils, et al.
Publicado: (2023)

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
por: Tönges, Lars, et al.
Publicado: (2022)

Parkinson’s disease between internal medicine and neurology
por: Csoti, Ilona, et al.
Publicado: (2015)

Editorial: Prodromal Parkinson's Disease
por: Crosiers, David, et al.
Publicado: (2021)

Association Between Dopaminergic Medications and the Evolution of REM Sleep Behavior Disorder in Parkinson's Disease
por: Cao, Ruihua, et al.
Publicado: (2022)

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022)

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies
por: Raeder, Vanessa, et al.
Publicado: (2023)

Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome
por: Grund, K. E., et al.
Publicado: (2023)

Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)
por: Peball, Marina, et al.
Publicado: (2019)

Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment
por: Borroto-Escuela, Dasiel O., et al.
Publicado: (2019)

In vivo Illustration of Altered Dopaminergic and GABAergic Systems in Early Parkinson's Disease
por: Takashima, Hirotsugu, et al.
Publicado: (2022)

Dry eye in Parkinson's disease: a narrative review
por: Ungureanu, Larisa, et al.
Publicado: (2023)

Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
por: Regensburger, Martin, et al.
Publicado: (2023)

Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
por: Sportelli, Carolina, et al.
Publicado: (2020)

Dopaminergic Modulation of Sensory Attenuation in Parkinson's Disease: Is There an Underlying Modulation of Beta Power?
por: Macerollo, Antonella, et al.
Publicado: (2019)

Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
por: Auffret, Manon, et al.
Publicado: (2023)

Glucocerebrosidase mutations and Parkinson disease
por: Vieira, Sophia R. L., et al.
Publicado: (2022)

The heterogeneity of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2023)

Treadmill training and physiotherapy similarly improve dual task gait performance: a randomized-controlled trial in Parkinson’s disease
por: Gaßner, Heiko, et al.
Publicado: (2022)

Brainstem Raphe Alterations in TCS: A Biomarker for Depression and Apathy in Parkinson's Disease Patients
por: Richter, Daniel, et al.
Publicado: (2018)

Hyposmia as a marker of (non-)motor disease severity in Parkinson’s disease
por: Roos, Dareia S., et al.
Publicado: (2019)

Flavor perception and the risk of malnutrition in patients with Parkinson’s disease
por: Roos, Dareia S., et al.
Publicado: (2018)

Treatment of Parkinson’s disease in the advanced stage
por: Ossig, C., et al.
Publicado: (2013)

Small intestine dysfunction in Parkinson’s disease
por: Dutkiewicz, Justyna, et al.
Publicado: (2015)

Neuroprotection in Parkinson’s disease: facts and hopes
por: Salamon, András, et al.
Publicado: (2019)

Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease
por: Cavallieri, Francesco, et al.
Publicado: (2021)

Is nigrostriatal dopaminergic deficit necessary for Holmes tremor to develop? The DaTSCAN and IBZM SPECT study
por: Gajos, Agata, et al.
Publicado: (2017)

A smartphone-based tapping task as a marker of medication response in Parkinson’s disease: a proof of concept study
por: Broeder, Sanne, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_01rhmpi3ec5c5sbl2cab4r5ki0